UK faces mandatory in vivo radiotherapy dose checks
This article was originally published in Clinica
The UK is facing calls for routine in vivo radiotherapy dosimetry checks to be made mandatory, in light of the "small proportion" of errors that continue to occur among the more than four million radiotherapy doses given annually. The alarm was raised today by the chief medical officer, Sir Liam Donaldson, with the publication of his 2006 report on the state of public health.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.